文献速递肾小球疾病遗传性与小管间质肾病

SEISMIC峰会:C3G肾病与IC-MPGN诊疗可及性多利益相关方共识

SEISMIC: a multistakeholder summit addressing access issues in diagnosis and treatment of C3G nephropathy and IC-MPGN.
PubMed 文献 · Kidney Int · 2026-08-28

C3G与原发性IC-MPGN是超罕见病,替代补体途径失调是核心机制。靶向近端补体级联的iptacoplan与pegcetacoplan已分别获批用于C3G和C3G/IC-MPGN。2025年7月SEISMIC峰会汇集专家与患者,围绕及时诊断、新药管理策略及治疗可及性障碍提出建议。

要点

  • C3G与IC-MPGN为超罕见补体介导肾病,治疗需求远未满足。
  • iptacoplan与pegcetacoplan靶向补体级联近端,已获批对应适应症。
  • 峰会提出及时诊断、管理策略更新和克服可及性障碍三方面建议。

核心结论

  • SEISMIC峰会就C3G与IC-MPGN的及时诊断、新药纳入临床实践及公平可及性形成多利益相关方建议。

研究设计与样本

  • 2025年7月召开的SEISMIC峰会汇集了多学科专家与患者,围绕3项目标进行讨论并形成建议报告。

主要发现

  • C3G与原发性IC-MPGN为超罕见病谱,疾病负担显著且安全有效治疗需求巨大。
  • 替代补体途径失调与过度激活是该病谱的潜在病理生理机制。
  • iptacoplan与pegcetacoplan分别获批用于C3G和C3G/IC-MPGN,靶向补体级联近端步骤。

临床怎么用

  • 肾内科应关注C3G与IC-MPGN的及时诊断,并评估将靶向补体药物纳入临床实践的时机与公平性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

C3 glomerulopathy (C3G)-primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) is an ultrarare disease spectrum associated with a significant health burden and for which there is a huge unmet need for safe and effective treatment. The underlying pathophysiology is dysregulation and overactivation of the alternative complement pathway. Two new therapeutic agents, iptacoplan and pegcetacoplan, that target proximal steps in the cascade, have demonstrated to be effective and have been approved for use in patients with C3G alone and with C3G/IC-MPGN, respectively. A key challenge to the nephrology community is how to incorporate these disease-modifying drugs into clinical practice in a timely and equitable manner. This report summarizes the deliberations and recommendations that emerged from the Addressing Access Issues in Diagnosis and Treatment of C3G Nephropathy and IC-MPGN (SEISMIC) summit in July 2025. The meeting assembled a broad panel of experts and patients and addressed the following 3 aims: (i) define issues in proper and timely diagnosis of this complex disease spectrum, (ii) assess management strategies in light of the availability of this new class of therapeutic agents, and (iii) identify barriers to access to care and treatment with these new therapeutic agents and design strategies to surmount them.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Nester C, Tarnoff J, Brisendine S, et al. SEISMIC: a multistakeholder summit addressing access issues in diagnosis and treatment of C3G nephropathy and IC-MPGN. Kidney Int. 2026. PMID: 42660226. doi:10.1016/j.kint.2026.07.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。